Alice Lione – Pagina 169 – AMD

Alice Lione

Marzo 22, 2021 Alice Lione

Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes

Lee MMY, Ghouri N, McGuire DK, et al.
Diabetes Care. 2021;dc203007

Leggi

Marzo 22, 2021 Alice Lione

NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction

Adler AI, Douch E, Dunning L, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00072-3

Leggi

Marzo 15, 2021 Alice Lione

Cardiovascular consequences of gestational diabetes

Green JB
Circulation. 2021;143(10):988-990

Leggi

Marzo 15, 2021 Alice Lione

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Davies M, Færch L, Jeppesen OK, et al.
Lancet. 2021;S0140-6736(21)00213-0

Leggi

Marzo 15, 2021 Alice Lione

Gestational diabetes history and glucose tolerance after pregnancy associated with coronary artery calcium in women during midlife – The CARDIA Study

Gunderson EP, Sun B, Catov JM, et al.
Circulation. 2021;143(10):974-987

Leggi

Marzo 15, 2021 Alice Lione

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

von Herrath M, Bain SC, Bode B, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00019-X

Leggi

Marzo 15, 2021 Alice Lione

A pragmatic, randomized clinical trial of gestational diabetes screening

Hillier TA, Pedula KL, Ogasawara KK, et al.
N Engl J Med. 2021;384(10):895-904

Leggi

Marzo 9, 2021 Alice Lione

Heterogeneous long-term trajectories of glycaemic control in type 1 diabetes

Miller RG, Orchard TJ, Onengut-Gumuscu S, et al.
Diabet Med. 2021;e14545

Leggi

Marzo 15, 2021 Alice Lione

Sodium glucose co-transporter-2 (SGLT2) inhibitors and the risk of diabetic ketoacidosis: an example of complementary evidence for rare adverse events

Alkabbani W, Pelletier R, Gamble JM
American Journal of Epidemiology. Pub. online 6 March 2021

Leggi

Marzo 9, 2021 Alice Lione

Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58

Cahn A, Raz I, Leiter LA, et al.
Diabetes Care. 2021;dc202492

Leggi